On October 28, 2024, Research Team from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"), HKEX stock code: 01541.HK), announced that preclinical study data of IMM2520 were published in the journal Heliyon under the title "IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy".

IMM2520 is a CD47 and PD-L1 bispecific molecule for the treatment of solid tumors. IMM2520 consists of a PD-L1 antibody with an engineered ADCC-enhanced IgG1 Fc region, linked to the CD47-binding domain used in IMM01 at the N-terminus of heavy chains. This unique structure allows our CD47-based bispecific molecules to avoid RBC binding, thus enabling the adoption of an ADCC-enhanced IgG1 Fc fragment to fully activate macrophages and induce enhanced ADCP and ADCC activity, resulting in potent integrated antitumor immune responses.

IMM2520 has been approved by China NMPA, the US FDA to carry out clinical trials, and holds the patents of China, Japan and US. Patents of the EU and other countries/regions is also in progress.

We have dosed the first patient at 0.1 mg/kg dose level on March 23, 2023 in the Phase I study of IMM2520 targeting solid tumor indications, with a particular focus on those solid tumors generally resistant or not sensitive to the currently available immunotherapies. As of June 30, 2024, 24 patients of dose escalation study were enrolled and dosed.  Preliminary data has demonstrated that IMM2520 is safe and well tolerated. As of June 30, 2024, one PR and 2 SDs with more than 10% tumor shrinkage were observed.

Founder and chairman of ImmuneOnco

Dr. Tian, Wenzhi said:

"We are delighted that our IMM2520 preclinical study data were published in the journal Heliyon. IMM2520 is an antibody-receptor recombinant protein (mAb-Trap) that targets both CD47 and PD-L1. We believe that IMM2520 has great clinical development value, and we will actively promote clinical trial research, actively explore differentiated development in solid tumor indications such as NSCLC, CRC, GC and HNSCC, and strive to bring it to the market to benefit cancer patients as soon as possible, "